Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
These findings highlight the relevance of gene expression profiling in HER2-positive breast cancer and support biomarker-driven patient selection. Long-term PATRICIA results validate the potential of non-chemotherapy-based approaches in HR-positive/HER2-positive MBC.
Authors
- Bárbara Adamo (ORCID: https://orcid.org/0000-0001-7129-8156)
- Pablo Tolosa (ORCID: https://orcid.org/0000-0002-3747-4766)
- Antonia Perelló (ORCID: https://orcid.org/0000-0003-4137-8790)
- Xavier González (ORCID: https://orcid.org/0000-0002-5797-7037)
- María González‐Rodríguez
- Sònia Pernas (ORCID: https://orcid.org/0000-0002-1485-5080)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- J.M. Ferrero-Cafiero (ORCID: https://orcid.org/0000-0001-8796-8812)
- Blanca González‐Farré (ORCID: https://orcid.org/0000-0002-1796-7248)
- Jordi Canes (ORCID: https://orcid.org/0000-0002-1309-5745)
- T. Pascual
- Lorea Villanueva (ORCID: https://orcid.org/0000-0003-1858-7076)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- J. Cortés
- Laia Paré (ORCID: https://orcid.org/0000-0002-4904-558X)
- Eduardo Martínez de Dueñas (ORCID: https://orcid.org/0000-0003-0110-4816)
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- Mireia Melé (ORCID: https://orcid.org/0000-0002-3408-8018)
- Patricia Villagrasa (ORCID: https://orcid.org/0000-0002-8662-3641)
- Paolo Giovanni Nuciforo (ORCID: https://orcid.org/0000-0003-1380-0990)
- E. Ciruelos
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Miguel Á. Galán (ORCID: https://orcid.org/0000-0002-6695-1509)
- P. Galván
Institutions
- Hospital Clínic de Barcelona (ES)
- Solti (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105572
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Pfizer